Assessment of genotoxicity of herbal medicinal products: Application of the “bracketing and matrixing” concept using the example of Valerianae radix (valerian root)

Abstract

An assessment of genotoxicity is a precondition for marketing authorization respectively registration of herbal medicinal products (HMPs), as well as for inclusion into the 'Community list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products' established by the European Commission in accordance with Directive 2001/83/EC as amended, and based on proposals from the Committee on Herbal Medicinal Products (HMPC). In the 'Guideline on the assessment of genotoxicity of herbal substances/preparations' (EMEA/HMPC/107079/2007) HMPC has described a stepwise approach for genotoxicity testing, according to which the Ames test is a sufficient base for the assessment of genotoxicity in case of an unequivocally negative result. For reducing efforts for testing of individual herbal substances/preparations, HMPC has also developed the 'guideline on selection of test materials for genotoxicity testing for traditional herbal medicinal products/herbal medicinal products' (EMEA/HMPC/67644/2009) with the aim to allow testing of a standard range of test materials which could be considered representative of the commonly used preparations from a specific herbal drug according to a 'bracketing/matrixing' approach. The purpose of this paper is to provide data on the practical application of this bracketing and matrixing concept using the example of Valerianae radix, with the intention of facilitating its inclusion in the "Community list". Five extraction solvents, representing the extremes of the polarity range and including also mid-range extraction solvents, were used, covering the entire spectrum of phytochemical constituents of Valerianae radix, thereby including polar and non-polar constituents. Extracts were tested in the Ames test according to all relevant guidelines. Results were unequivocally negative for all extracts. A review of the literature showed that this result is in accordance with the available data, thus demonstrating the lack of a genotoxic potential. In conclusion the two guidelines on genotoxicity provide a practically applicable concept. Valerianae radix has no genotoxic potential, supporting its use in HMPs and its inclusion in the Community list.

Cancer Prevention and Health Benefices of Traditionally Consumed Borago officinalis Plants

“…The complexity of plant composition and the human digestion process requires validated models that represent this relation as closely and in a manner as valuable for research as possible. For this reason, we have selected the in vivo Drosophila melanogaster and in vitro HL-60 human cancer cell system as two complementary, sensitive, low-cost and rapid eukaryotic assays, able to detect the potential mutagenic and carcinogenic effects of tested compounds [ 27 , 28 , 29 , 30 ].…”

Assessment of the Acute and Subchronic Toxicity and Mutagenicity of Sideritis scardica Griseb. Extracts

“…These data may be used during authorization or registration procedures as well-established use (WEU) or traditionally used (THMP) herbal medicinal products in the European Community, and might provide valuable information particularly in respect to therapeutic use, tolerability, and toxicity [13,14,15,16]. Attention should be paid to biological effects that are difficult to detect clinically.…”

Hazard assessment of Maerua subcordata (Gilg) DeWolf. for selected endpoints using a battery of in vitro tests

“…Thus, as the EU guidelines for herbal products define the Ames test as the primary endpoint to judge the genotoxicity (EMEA, 2007;Ouedraogo et al, 2012;Kelber et al, 2014), the results of the present study can be used to support the conclusion that these extracts may not raise a concern with respect to the genotoxicity of M. subcordata.…”